PharmAGRI Capital Partners Targets $10 Billion Federal Procurement Opportunity for Onshored Plant-Based Prescription Drugs Bright Green Corporation “BGXXQ” Q and A - Seite 2

Q: What will PharmAGRI gain from its merger with Bright Green Corporation (OTC: BGXX)?

A: Following its merger with Bright Green Corporation, PharmAGRI Capital Partners absorbs and maintains the BGXX DEA registrations, Board of Pharmacy licensure, Nasdaq history, and audited financials. These assets provide a federally compliant foundation for relisting and scaling domestic prescription drug manufacturing. The merger is being executed under a court-supervised restructuring plan, ensuring procedural integrity and strategic continuity.

Q: Was Bright Green Corporation a good company to merge with?

A: Not in its original form. Bright Green Corporation had been poorly managed—its capital raises were mishandled, warrant structures were excessive, and it was late in pivoting away from cannabis. These weaknesses, however, created a strategic opening.

Q: Will PharmAGRI be listed on Nasdaq?

A: Yes. PharmAGRI is preparing a Form S-1 registration statement with the U.S. Securities and Exchange Commission and intends to relist under a new ticker symbol. The company meets Nasdaq’s governance, audit, and operational standards and is aligned with federal sourcing mandates.

Q: Are there any lock-up restrictions on PharmAGRI shares?

A: No. Non-affiliate shareholders will face no lock-up restrictions, ensuring full liquidity upon relisting. This structure supports transparent trading, institutional access, and investor confidence.

Q: What is the market opportunity PharmAGRI is targeting?

A: PharmAGRI is focused on capturing a $10 billion total addressable market (TAM) in federal procurement of plant-based prescription drugs currently imported from overseas. While this segment is modest compared to the broader pharmaceutical industry, it represents a high-barrier, high-value opportunity for sovereign infrastructure. Driven by DEA quota to prescription drugs the company can focus on infrastructure scale, there is a ready market supporting the production and manufactured pharmaceuticals by government contracts as were displace the imports the predictability is certain.

Q: How does PharmAGRI plan to execute at scale?

A: PharmAGRI’s vertically integrated “seed to prescription drug” model aligns DEA quota with federal contract obligations, enabling predictable scaling and secure sourcing. The company has executed a Letter of Intent with Tesla to deploy up to 10,000 Optimus Gen3+ humanoid robots across its SuperPharm and CEA facilities, automating labor and ensuring diversion control.